The PSA test may also be used as a screening tool for
prostate cancer. However, this use is controversial. Talk to your doctor about the risks and benefits of the PSA test, and your personal risk factors for prostate cancer.
Wait several weeks after successful treatment of prostate infections.
Some medications can lower PSA levels. Talk to your doctor about any medications, herbs, or supplements you take.
Description of Test
You will be asked to sit. An area inside your elbow will be cleaned with an antiseptic wipe. A large band will be tied around your arm. The needle will then be inserted into a vein. A tube will collect the blood from the needle. The band on your arm will be removed. Once all the blood is collected, the needle will be removed. Some gauze will be placed over the site to help stop bleeding. You may also be given a bandage to place over the site.
Fang J, Metter EJ, et al. PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/mL.
How did the USPSTF arrive at this recommendation? US Preventative Services Task Force website. Available at: ...(Click grey area to select URL) Accessed March 6, 2018
PSA testing for the pretreatment staging and posttreatment management of prostate cancer: 2013 revision of 2009 best practice statement. American Urological Association website. Available at: ...(Click grey area to select URL) Accessed March 6, 2018.
Prostate-specific antigen (PSA) Test. National Cancer Institute website. Available at: ...(Click grey area to select URL) Updated October 4, 2017. Accessed March 6, 2018.
Screening for prostate cancer: current recommendation. US Preventative Services Task Force website. Available at: ...(Click grey area to select URL) Updated May 2012. Accessed March 6, 2018.
Stephan C, Stroebel G, et al. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
5/6/2009 DynaMed's Systematic Literature Surveillance ...(Click grey area to select URL) Schröder FH, Hugosson J, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.
Last reviewed March 2018 by
EBSCO Medical Review Board
Alan Drabkin, MD Last Updated: 4/29/2014